Surgery Partners Reports Weak Q4 Results and Cautious 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy SGRY?
Source: Benzinga
Surgery Partners' stock fell 12.91% as it crossed below the 5-day SMA, reaching its lowest point in over five years.
The company reported disappointing Q4 results, with adjusted earnings of 12 cents per share, significantly below the consensus estimate of 30 cents. Additionally, revenue forecasts for FY26 were notably lower than anticipated, leading to a 20% decline in stock value. Management's cautious outlook for 2026, projecting net revenue between $3.35 billion and $3.45 billion, reflects ongoing challenges in the market.
These results indicate significant operational pressures and a potential decline in investor confidence, prompting a need for Surgery Partners to adapt its strategies to improve profitability and market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGRY
Wall Street analysts forecast SGRY stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 11.600
Low
18.00
Averages
26.30
High
36.00
Current: 11.600
Low
18.00
Averages
26.30
High
36.00
About SGRY
Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of approximately 162 surgical facilities comprised of 175 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 30 states, including short-stay surgical hospitals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surgery Partners Faces Margin Pressures Amid Guidance Downgrade
- Guidance Downgrade: Following disappointing Q4 2025 results, Surgery Partners' previously optimistic margin expansion outlook has been significantly undermined, leading to a sharp stock price drop in March 2026, indicating a loss of market confidence in the company's growth trajectory.
- Cost Pressures Revealed: Despite CEO Eric Evans expressing high confidence in the 2025 growth outlook, the latest FY guidance indicates that shifts in payer mix and anesthesia cost dynamics have begun to pressure margins, suggesting potential undisclosed risks by management.
- Acquisition Target Missed: The company aimed to deploy $200 million for acquisitions in 2025 but only managed to deploy $182 million, highlighting challenges faced in business expansion and further eroding investor confidence.
- Legal Investigation Initiated: Due to the disparity between Surgery Partners' forward guidance and actual performance, Levi & Korsinsky, LLP is investigating whether management was aware of these cost pressures when issuing forward guidance, potentially impacting shareholders' legal rights.
See More
Surgery Partners Reports 4.2% Decline in Q4 Adjusted EBITDA
- Financial Performance Gap: Surgery Partners reported an Adjusted EBITDA of $136.4 million for Q4 2025, reflecting a 4.2% decline compared to the previous year, creating a stark contrast with management's earlier profit expectations and undermining investor confidence.
- Negative Market Reaction: Despite management's claims of a 6.1% growth in Adjusted EBITDA for Q3 and a 16.6% margin, the decline in Q4 led to a sharp drop in SGRY shares, indicating market concerns over the company's future profitability.
- Legal Investigation Initiated: Following discrepancies in financial reporting, Levi & Korsinsky LLP is investigating potential securities law violations by Surgery Partners, encouraging affected shareholders to provide information for legal recourse.
- Uncertain Outlook: Management's previous optimism regarding future margin expansion is now clouded by the recent performance decline, raising doubts among investors about the company's growth prospects and potentially impacting its long-term investment appeal.
See More
Activist Investor Calls for Surgery Partners to Sell Hospitals
- Asset Sale Proposal: Activist investor Ortelius Advisors is urging Surgery Partners to divest all of its surgical hospitals, which is expected to generate billions in asset sales, thereby providing the capital necessary for stock buybacks, debt reduction, and improved creditworthiness.
- Management Overhaul: Ortelius is also calling for a refresh of Surgery Partners' board and the installation of a new management team, aiming to enhance corporate governance and strengthen market competitiveness through a strategic review.
- Financial Outlook Improvement: Ortelius highlighted that after the sale of hospitals, the remaining entity would focus on ambulatory surgery centers, which are projected to exhibit stronger revenue growth, higher EBITDA margins, and larger free cash flow yields, thus warranting an expanded enterprise value to EBITDA multiple.
- Market Reaction: Although Surgery Partners has not yet responded to these proposals, the company is set to present at the Barclays 28th Annual Global Healthcare Conference, which may draw investor attention to its future strategic direction.
See More
Surgery Partners Faces Value Destruction and Accountability Demands
- Shareholder Value Loss: Over the past five years, Surgery Partners' stock price has plummeted by 67%, lagging benchmarks by 108 percentage points, indicating severe underperformance and a significant decline in shareholder confidence.
- Peer Comparison Deficit: Compared to HCA Healthcare and Tenet Healthcare, Surgery Partners has underperformed by 276 and 413 percentage points in total shareholder returns, highlighting a critical need for strategic measures to regain competitive standing in the industry.
- Asset Divestiture Potential: Ortelius suggests that divesting all surgical hospitals could generate billions in asset sales, providing the necessary capital for stock repurchases and debt reduction, thereby improving the company's financial health and creditworthiness.
- Need for Management Change: Ortelius calls for substantial changes in the board and management team to address serious governance and execution failures, aiming to restore shareholder trust in the company's leadership.
See More
Surgery Partners to Present at Barclays Healthcare Conference
- Investor Meeting Schedule: Surgery Partners is set to present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, at 2:30 p.m. Eastern Time, which is expected to attract significant investor interest.
- Webcast Availability: The event will be available via a simultaneous webcast through the company's investor relations section, allowing investors to access the replay for a limited time post-event, ensuring broad dissemination and transparency of information.
- Company Background: Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners is one of the largest surgical services companies in the U.S., operating over 200 locations across 30 states, focusing on high-quality, cost-effective surgical and ancillary care solutions.
- Business Model Advantage: The company employs a differentiated outpatient delivery model aimed at meeting the needs of both patients and physicians, significantly enhancing its market position and growth potential amid rising demand for healthcare services.
See More
SURGERY PARTNERS INC: UBS LOWERS TARGET PRICE FROM $29 TO $21
Surgery Partners Inc. Update: The company has announced a significant reduction in its target price.
New Target Price: The target price has been lowered from $29 to $21.
See More
Surgery Partners Faces Margin Pressures Amid Guidance Downgrade
- Guidance Downgrade: Following disappointing Q4 2025 results, Surgery Partners' previously optimistic margin expansion outlook has been significantly undermined, leading to a sharp stock price drop in March 2026, indicating a loss of market confidence in the company's growth trajectory.
- Cost Pressures Revealed: Despite CEO Eric Evans expressing high confidence in the 2025 growth outlook, the latest FY guidance indicates that shifts in payer mix and anesthesia cost dynamics have begun to pressure margins, suggesting potential undisclosed risks by management.
- Acquisition Target Missed: The company aimed to deploy $200 million for acquisitions in 2025 but only managed to deploy $182 million, highlighting challenges faced in business expansion and further eroding investor confidence.
- Legal Investigation Initiated: Due to the disparity between Surgery Partners' forward guidance and actual performance, Levi & Korsinsky, LLP is investigating whether management was aware of these cost pressures when issuing forward guidance, potentially impacting shareholders' legal rights.
See More
Surgery Partners Reports 4.2% Decline in Q4 Adjusted EBITDA
- Financial Performance Gap: Surgery Partners reported an Adjusted EBITDA of $136.4 million for Q4 2025, reflecting a 4.2% decline compared to the previous year, creating a stark contrast with management's earlier profit expectations and undermining investor confidence.
- Negative Market Reaction: Despite management's claims of a 6.1% growth in Adjusted EBITDA for Q3 and a 16.6% margin, the decline in Q4 led to a sharp drop in SGRY shares, indicating market concerns over the company's future profitability.
- Legal Investigation Initiated: Following discrepancies in financial reporting, Levi & Korsinsky LLP is investigating potential securities law violations by Surgery Partners, encouraging affected shareholders to provide information for legal recourse.
- Uncertain Outlook: Management's previous optimism regarding future margin expansion is now clouded by the recent performance decline, raising doubts among investors about the company's growth prospects and potentially impacting its long-term investment appeal.
See More
Activist Investor Calls for Surgery Partners to Sell Hospitals
- Asset Sale Proposal: Activist investor Ortelius Advisors is urging Surgery Partners to divest all of its surgical hospitals, which is expected to generate billions in asset sales, thereby providing the capital necessary for stock buybacks, debt reduction, and improved creditworthiness.
- Management Overhaul: Ortelius is also calling for a refresh of Surgery Partners' board and the installation of a new management team, aiming to enhance corporate governance and strengthen market competitiveness through a strategic review.
- Financial Outlook Improvement: Ortelius highlighted that after the sale of hospitals, the remaining entity would focus on ambulatory surgery centers, which are projected to exhibit stronger revenue growth, higher EBITDA margins, and larger free cash flow yields, thus warranting an expanded enterprise value to EBITDA multiple.
- Market Reaction: Although Surgery Partners has not yet responded to these proposals, the company is set to present at the Barclays 28th Annual Global Healthcare Conference, which may draw investor attention to its future strategic direction.
See More
Surgery Partners Faces Value Destruction and Accountability Demands
- Shareholder Value Loss: Over the past five years, Surgery Partners' stock price has plummeted by 67%, lagging benchmarks by 108 percentage points, indicating severe underperformance and a significant decline in shareholder confidence.
- Peer Comparison Deficit: Compared to HCA Healthcare and Tenet Healthcare, Surgery Partners has underperformed by 276 and 413 percentage points in total shareholder returns, highlighting a critical need for strategic measures to regain competitive standing in the industry.
- Asset Divestiture Potential: Ortelius suggests that divesting all surgical hospitals could generate billions in asset sales, providing the necessary capital for stock repurchases and debt reduction, thereby improving the company's financial health and creditworthiness.
- Need for Management Change: Ortelius calls for substantial changes in the board and management team to address serious governance and execution failures, aiming to restore shareholder trust in the company's leadership.
See More
Surgery Partners to Present at Barclays Healthcare Conference
- Investor Meeting Schedule: Surgery Partners is set to present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, at 2:30 p.m. Eastern Time, which is expected to attract significant investor interest.
- Webcast Availability: The event will be available via a simultaneous webcast through the company's investor relations section, allowing investors to access the replay for a limited time post-event, ensuring broad dissemination and transparency of information.
- Company Background: Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners is one of the largest surgical services companies in the U.S., operating over 200 locations across 30 states, focusing on high-quality, cost-effective surgical and ancillary care solutions.
- Business Model Advantage: The company employs a differentiated outpatient delivery model aimed at meeting the needs of both patients and physicians, significantly enhancing its market position and growth potential amid rising demand for healthcare services.
See More
SURGERY PARTNERS INC: UBS LOWERS TARGET PRICE FROM $29 TO $21
Surgery Partners Inc. Update: The company has announced a significant reduction in its target price.
New Target Price: The target price has been lowered from $29 to $21.
See More
